Page 312 - Read Online

Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 17 of 18

134. Tsujita Y, Horiguchi A, Tasaki S, Isono M, Asano T, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of
Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 17 of 18 bladder cancer cells.
Oncol Rep 2017;38:2197-204.
135. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell
carcinoma. Br J Cancer 2010;102:1592-9.
136. Huang Y, Zhou X, Liu A, Li S, Wang X, et al. Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue
squamous cell carcinoma proliferation and apoptosis in vitro and in vivo. Zhonghua Kou Qiang Yi Xue Za Zhi 2014;49:308-13. (in
Chinese)
137. Zhou X, Ren Y, Liu A, Han L, Zhang K, et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell
carcinoma growth in vitro and in vivo. Oncol Rep 2014;31:2173-80.
138. Bai H, Wang C, Qi Y, Xu J, Li N, et al. Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling
pathway. BMC Cancer 2019;19:454.
139. Hou J, Lv A, Deng Q, Zhang G, Hu X, et al. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the
JAK2/STAT3 signaling pathway. Oncol Rep 2019;41:753-64.
140. Zhou Q, Jiang H, Zhang J, Yu W, Zhou Z, et al. Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the
stat3 pathway. Cancer Manag Res 2018;10:6339-55.
141. Zhou X, Ren Y, Liu A, Jin R, Jiang Q, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR21
axis. Sci Rep 2014;4:7461.
142. Cheng CC, Shi LH, Wang XJ, Wang SX, Wan XQ, et al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin
resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol 2018;53:339-48.
143. Tang YJ, Sun ZL, Wu WG, Xing J, He YF, et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian
cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Genet Mol Res 2015;14:2450-60.
144. Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, et al. Combined inhibition of Notch and JAK/STAT is superior to monotherapies
and impairs pancreatic cancer progression. Carcinogenesis 2013;35:859-66.
145. Fu LX, Lian QW, Pan JD, Xu ZL, Zhou TM, et al. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of
gallbladder cancer cells via inhibition of JAK2/STAT3 signaling. J Biol Regul Homeost Agents 2017;31:51-8.
146. Faouzi M, Chopin V, Ahidouch A, Ouadid-Ahidouch H. Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced
proliferation in breast cancer cells. J Membr Biol 2010;234:47-56.
147. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, et al. Novel drug discovery system for cancer stem cells in human squamous cell
carcinoma of the esophagus. Oncol Rep 2014;31:1133-8.
148. Xie L, Zeng Y, Dai Z, He W, Ke H, et al. Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib
induced cell death. Int J Biol Sci 2018;14:577-85.
149. Zhang L, Xu LJ, Zhu J, Li J, Xue BX, et al. ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of
androgenindependent prostate cancer. Mol Med Rep 2018;17:7045-54.
150. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a
murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20.
151. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in
myelofibrosis. J Clin Oncol 2011;29:789-96.
152. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, et al. Safety and efficacy of fedratinib in patients with primary or secondary
myelofibrosis: a randomized clinical trial. JAMA Oncol 2015;1:643-51.
153. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis
previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol
2017;4:e317-24.
154. Li SD, Ma M, Li H, Waluszko A, Sidorenko T, et al. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in
JAK2 and JAK3 with therapeutic implications. Genome Med 2017;9:89.
155. Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, et al. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in nonsmall cell lung
carcinoma cells with mutated EGF receptor. Oncotarget 2015;6:14329-43.
156. Chen D, Zhang F, Wang J, He H, Duan S, et al. Biodegradable nanoparticles mediated Co-delivery of erlotinib (ELTN) and fedratinib
(FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer (NSCLC) via suppression of the JAK2/STAT3 signaling
pathway. Front Pharmacol 2018;9:1214.
157. Gorshkov K, Sima N, Sun W, Lu B, Huang W, et al. Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using
approved drugs and bioactive compounds. Transl Oncol 2019;12:441-52.
158. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell
self-renewal. J Clin Invest 2014;124:553-63.
159. Lin C, Cao W, Ren Z, Tang Y, Zhang C, et al. GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling
activation in HNSCC. Oncoimmunology 2017;6:e1353860.
160. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, et al. Effect of filgotinib vs placebo on clinical response in patients
with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized
clinical trial. JAMA 2019;322:315-25.
161. Tarrant JM, Galien R, Li W, Goyal L, Pan Y, et al. Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid